000078 海王生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.501-43.924-19.5351.595-4.760
总资产报酬率 ROA (%)0.142-4.930-2.7810.241-0.713
投入资产回报率 ROIC (%)0.261-9.057-4.9460.409-1.221

边际利润分析
销售毛利率 (%)10.0599.75710.01710.71311.612
营业利润率 (%)1.285-4.031-2.2591.3670.791
息税前利润/营业总收入 (%)3.498-1.4140.1383.3702.893
净利润/营业总收入 (%)0.693-4.720-2.6200.628-0.103

收益指标分析
经营活动净收益/利润总额(%)75.1925.843-6.142126.015329.717
价值变动净收益/利润总额(%)-4.2851.89710.15713.02025.155
营业外收支净额/利润总额(%)0.585-0.655-0.1672.654-18.373

偿债能力分析
流动比率 (X)1.0431.0391.0621.0621.055
速动比率 (X)0.9140.9060.9200.9350.933
资产负债率 (%)86.61986.94583.14280.56581.144
带息债务/全部投入资本 (%)81.42881.93075.51471.744--
股东权益/带息债务 (%)21.68220.94931.34837.38932.865
股东权益/负债合计 (%)11.07810.69115.56619.21818.240
利息保障倍数 (X)1.586-0.5460.0581.7141.300

营运能力分析
应收账款周转天数 (天)184.693178.769179.857156.6360.000
存货周转天数 (天)43.18643.11742.22337.8030.000